Search global stocks & ETFs...Ctrl K

Learn Mode

SRPT - Sarepta Therapeutics Inc

28

$17.89

-$0.79 (-4.229%)

5/15/26, 4:59 PM

Score

2.48/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

SRPT

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$1.88B

Industry

Biotechnology

EPS (TTM)

$0.53

P/E (TTM)

28.93

Div & Yield

FCF Payout Ratio

P/S (TTM)

0.86

P/B

1.25

Diluted Shares

121.92M

Ex-Dividend

Next Earnings

08-04

Forward P/E

10.01

Payout Ratio

P/FCF (TTM)

17.39

FCF Yield

5.75%

Earnings Yield

3.46%

52 Week Range

Score Card

Explore Scores Tab

2.48

Bad

Sarepta Therapeutics Inc has seen its revenue decline by -2.2% over the past year, which means the company is losing sales/customers. Also, it has seen its diluted average shares outstanding increase by 25.22% over the past year, which suggests the company is diluting shareholders.

Valuation Model

Key Score

4.00

Good

Management

3.00

Average

Growth

5.00

Very Good

Profitability

3.00

Average

Fin. Health

4.00

Good

Dividends

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form 13F-HR

Unknown Form Type

Filed on 2026-05-13 16:22:44

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-06 16:10:17

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-06 16:01:49

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-30 13:09:56

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-29 15:13:57

Form ARS

Unknown Form Type

Filed on 2026-04-24 16:21:13

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-24 16:11:01

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-24 16:10:20

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 13:00:25

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-13 20:09:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-13 20:07:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-13 20:05:03

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$39.90

123.0%

Avg:

$22.61

26.4%

Low:

$5.05

-71.8%

(% change is relative to the current stock price: $17.89)

Analyst Recommendations

Go to Analyst Tab

3.42

Good

21%

Strong Buy (7)

18%

Buy (6)

45%

Hold (15)

12%

Sell (4)

Strong Sell (1)

About

Website
https://www.sarepta.com/
Address
215 First Street, Suite 415, Cambridge MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=873303

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

IPO Date

1997-06-04

Industry

Biotechnology

Total Employees

835

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

SRPT - Sarepta Therapeutics Inc

28

$17.89

-$0.79 (-4.229%)

2.48/5

Stock Unlock

Stock Profile

Score Card

Bad

Insider Transactions

Market News

Form 13F-HR

Filed on 2026-05-13 16:22:44

Form 8-K

Filed on 2026-05-06 16:10:17

Form 10-Q

Filed on 2026-05-06 16:01:49

Form SCHEDULE 13G

Filed on 2026-04-30 13:09:56

Form SCHEDULE 13G

Filed on 2026-04-29 15:13:57

Form ARS

Filed on 2026-04-24 16:21:13

Form DEFA14A

Filed on 2026-04-24 16:11:01

Form DEF 14A

Filed on 2026-04-24 16:10:20

Form SCHEDULE 13G/A

Filed on 2026-03-27 13:00:25

Form 4

Filed on 2026-03-13 20:09:03

Form 4

Filed on 2026-03-13 20:07:03

Form 4

Filed on 2026-03-13 20:05:03

Financials

Price Targets

123.0%

26.4%

-71.8%

Analyst Recommendations

About

Similar Stocks